Completing data — refresh the page later to see the latest
177325-13-2C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.ClCAOOISJXWZMLBN-PPHPATTJSA-NSafety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
UsesLevofloxacin Hydrochloride is a fluoroquinolone broad spectrum antibiotic. It is an inhibitor of two enzymes, DNA gyrase and topoisomerase IV.
PreparationThe existing synthesis process for levofloxacin hydrochloride involves a condensation reaction of levofluorocarboxylic acid and N-methylpiperazine under a catalyst to produce levofloxacin. The solvent is then evaporated, and the product is crystallized in a crystallization solvent and dried to obtain dried levofloxacin. Finally, levofloxacin is salted with hydrochloric acid and crystallized multiple times with ethanol to obtain levofloxacin hydrochloride. The existing synthesis process has the following problems: 1) It requires the prior preparation of levofloxacin crystals before salting with hydrochloric acid, making the process lengthy, cumbersome, and difficult to operate; 2) The use of a catalyst in the preparation of levofloxacin introduces impurities, resulting in low purity of the final levofloxacin hydrochloride, requiring further purification.
177325-13-2DTXSID80432709CHEMBL2237108